121 Echocardiographic changes in Fabry disease Table 1: FD patients’ characteristics (continued) All Men Women Cardiovascular risk factors† Smoking, n (%) 41 (45%) 17 (50%) 24 (41%) Obesity, n (%) 16 (17%) 4 (12%) 12 (21%) Diabetes, n (%) 1 (1%) 0 (0%) 1 (2%) Dyslipidemia, n (%) 20 (22%) 7 (21%) 13 (22%) Hypertension, n (%) 28 (30%) 9 (27%) 19 (33%) Cardiovascular (preventive) medication† ACE inhibitors or Angiotensin receptor blockers , n (%) 59 (64%) 22 (65%) 37 (64%) Thiazide diuretics, n (%) 15 (16%) 5 (15%) 10 (17%) Loop diuretics, n (%) 17 (19%) 6 (18%) 11 (19%) Potassium-sparing diuretics, n (%) 10 (11%) 3 (9%) 7 (12%) Beta-blockers, n (%) 24 (26%) 7 (21%) 17 (29%) Calcium channel blockers, n (%) 19 (21%) 6 (18%) 13 (22%) Statins, n (%) 20 (22%) 8 (24%) 12 (21%) † cardiovascular risk factors or the use of Cardiovascular (preventive) medication at any time during follow-up: - Obesity: Body Mass Index ≥ 30 kg/m2 - Smoking: patients who have ever smoked - Hypertension: use of antihypertensive medication or systolic blood pressure of >140 mmHg and/ or diastolic blood pressure of >90 mmHg, present at least two measurements - Dyslipidemia: elevated levels of total cholesterol (>6.5 mmol/l) or low density lipoprotein (LDL) cholesterol (>2.5 mmol/l) or triglycerides (>3.0 mmol/l) or low levels of high-density lipoprotein (HDL) cholesterol (men: <1.0 mmol/l, women <1.2 mmol/l), or medication prescribed for the indication dyslipidemia - Diabetes mellitus: type I or type II if reported in the medical chart or the use of anti-diabetic medication 4
RkJQdWJsaXNoZXIy MTk4NDMw